Robert B Den,Laura A Doyle,Karen E Knudsen
Robert B Den
Introduction: Bone seeking radiopharmaceuticals have been used for decades in the palliation of pain from bone metastases emerging from prostate cancer. Recent clinical evidence has demonstrated an improved survival in me...
Jean Hoffman-Censits,Wm Kevin Kelly
Jean Hoffman-Censits
Introduction: We summarize the development, definitive trials, and practical use of enzalutamide for practicing urologists and medical oncologists. The care paradigm for patients with metastatic castration resistant prost...
Practical guide to the use of abiraterone in castration resistant prostate cancer [0.03%]
去势抵抗性前列腺癌阿比特龙使用的实践指南
Elahe A Mostaghel,Daniel W Lin
Elahe A Mostaghel
Introduction: While androgen deprivation therapy remains the primary treatment modality for patients with metastatic prostate cancer, treatment is uniformly marked by progression to castration resistant prostate cancer (C...
Practical guide to immunotherapy in castration resistant prostate cancer: the use of sipuleucel-T immunotherapy [0.03%]
转移性去势抵抗性前列腺癌的sipuleucel-T免疫疗法
Leonard G Gomella,Francisco Gelpi-Hammerschmidt,Chandan Kundavram
Leonard G Gomella
Introduction: New treatment options for metastatic castration resistant prostate cancer (mCRPC) have become available over the last few years should primary treatments and androgen deprivation therapies fail. While histor...
David Leung,Saravanan Krishnamoorthy,Lawrence Schwartz et al.
David Leung et al.
Introduction: In conjunction with biomarkers, imaging is an important component of the diagnostic work up and subsequent management of men with prostate cancer. ...
Sohaib Al-Asaaed,Eric Winquist
Sohaib Al-Asaaed
Introduction: Castration resistant prostate cancer (CRPC) is the single common pathway to prostate cancer death. For men with symptomatic metastatic disease, docetaxel chemotherapy remains a standard of care. However, blo...
Intermittent androgen deprivation therapy for prostate cancer: translating randomized controlled trials into clinical practice [0.03%]
间断性雄激素剥夺治疗前列腺癌：如何在临床实践中开展随机对照试验
Shawn Dason,Christopher Brian Allard,Jing Gennie Wang et al.
Shawn Dason et al.
Introduction: Intermittent androgen deprivation therapy (IADT) for prostate cancer involves cycles of androgen deprivation therapy (ADT) with a period between cycles where testosterone is allowed to rise above castrate le...
Judd W Moul
Judd W Moul
Introduction: Androgen deprivation therapy (ADT) is the lynchpin of treatment for advanced prostate cancer. Prescribing physicians and patients have a choice between orchiectomy, luteinizing hormone releasing hormone (LHR...
Traditional androgen ablation approaches to advanced prostate cancer: new insights [0.03%]
前列腺癌传统雄激素剥夺疗法的新观点
Kyle O Rove,E David Crawford
Kyle O Rove
Introduction: Androgen deprivation therapy (ADT) is a mature therapy for the treatment of advanced prostate cancer, and yet despite many years of use, there is still much about its use, side effects, efficacy, and outcome...
The changing landscape of advanced and castration resistant prostate cancer: latest science and revised definitions [0.03%]
前列腺癌的治疗格局改变：最新科研成果及更新定义
Derya Tilki,Christopher P Evans
Derya Tilki
Introduction: One fifth of men with newly diagnosed prostate cancer present with locally advanced or metastatic disease. Androgen deprivation therapy (ADT) is the standard systemic therapy in these patients. Despite initi...